The FDA has approved the drug tradipitant (Nereus), which is an oral neurokinin-1 (NK-1) receptor antagonist. This drug is indicated for the prevention of motion-induced vomiting in adults. The approval was announced by Vanda Pharmaceuticals on Tuesday. It is the first new treatment for motion sickness in more than 40 years.